Ornilatex
Ornilatex: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Drug interactions
- 14. Analogs
- 15. Terms and conditions of storage
- 16. Terms of dispensing from pharmacies
- 17. Reviews
- 18. Price in pharmacies
Latin name: Ornilatex
ATX code: A05BA
Active ingredient: ornithine (Ornithine)
Producer: CJSC "PharmFirma" Sotex "(Russia)
Description and photo update: 2019-23-10
Ornilatex is a hypoammonic drug for parenteral use.
Release form and composition
The drug is produced in the form of a concentrate for the preparation of a solution for infusion: a transparent, colorless or pale yellow liquid (10 ml each in an ampoule made of light-shielding glass with a colored dot and a notch or with a colored break ring, additionally 1, 2 or 3 colored rings and / or alphanumeric coding and / or two-dimensional barcode; in a blister strip packaging 5 ampoules, in a cardboard box 1 or 2 cell packaging and instructions for the use of Ornilatex).
Concentrate composition for 1 ampoule (10 ml):
- active substance: ornithine aspartate (in terms of dry matter) - 5 g;
- additional components: water for injection - up to 10 ml.
Pharmacological properties
Pharmacodynamics
With liver damage and other diseases, ornithine reduces the increased content of ammonia in the body. The effect of the drug is due to its participation in the course of the ornithine cycle of Krebs urea formation (urea production from ammonia). Ornithine is a catalyst for enzymes such as carbamoyl phosphate synthetase (EC 6.3.4.16) and ornithine carbamoyltransferase (EC 2.1.3.3), and is also the basis for the production of urea. In addition, the agent activates the ornithine cycle of urea synthesis, which in turn also helps to reduce the concentration of ammonia. Promotes the production of insulin and growth hormone. Provides an improvement in protein metabolism against the background of diseases requiring parenteral nutrition.
Pharmacokinetics
In the process of in vivo studies, it was found that as a result of the metabolic transformation of ornithine aspartate, 2 active metabolites are formed - ornithine and aspartate. They have a short half-life (T 1/2) - 0.3–0.4 hours and are excreted by the kidneys through the urea cycle. In small amounts, aspartate is also excreted unchanged by the kidneys.
Indications for use
Ornilatex is intended for the treatment of the following hepatic pathologies:
- liver disease in acute and chronic form, occurring with hyperammonemia;
- hepatic encephalopathy (including as part of the complex treatment of such disorders of consciousness as precoma and coma).
Also, the drug is recommended for use as a corrective additive to parenteral nutrition products in patients with protein deficiency.
Contraindications
- severe renal failure (serum creatinine more than 3 mg / dL);
- lactation period;
- age up to 18 years;
- hypersensitivity to any component of the product.
Ornilatex, instructions for use: method and dosage
The solution prepared from the Ornilatex concentrate is injected intravenously (iv) by drop. The contents of the ampoules should be diluted in 500 ml of 0.9% sodium chloride infusion solution, 5% dextrose (glucose) solution or Ringer's solution.
The average daily therapeutic dose of ornithine is 20 g. In the treatment of hepatic encephalopathy, taking into account the severity of the condition, the dose of the drug can be increased to 40 g per day.
The maximum rate of intravenous infusion of ornithine should not exceed 5 g / h.
It is recommended to dilute no more than 30 g of the drug in 500 ml of infusion solution.
The course of therapy with Ornilatex is established in each case individually, depending on the severity of the general condition of the patient and the severity of hepatic pathology. Patients with severe liver dysfunction may need to monitor their well-being and adjust the infusion rate to eliminate the risk of nausea and vomiting.
Side effects
In extremely rare cases (less than 0.01%), during treatment with the drug, the development of such side effects as nausea, vomiting and allergic reactions may occur.
Overdose
Overdose symptoms may include aggravation of the severity of dose-dependent adverse effects.
In this condition, it is required to stop the administration of the drug and prescribe symptomatic treatment.
special instructions
When using a hypoammonoemic agent in large doses, the level of urea in blood plasma and urine should be monitored.
Influence on the ability to drive vehicles and complex mechanisms
Ornilatex does not adversely affect the patient's ability to drive a car and control other complex mechanisms.
Application during pregnancy and lactation
During pregnancy, the use of Ornilatex is allowed only under strict medical supervision, after a careful assessment of the benefit / risk ratio for the mother and the fetus.
During lactation, during therapy with Ornilatex, it is required to transfer the child to artificial feeding.
Pediatric use
There is no data on the use of Ornilatex in pediatric practice. For patients under 18 years of age, drug therapy is contraindicated.
With impaired renal function
Patients with severe renal insufficiency, with a serum creatinine level of more than 3 mg / dL, the use of the drug is contraindicated.
For violations of liver function
In the presence of severe functional impairment of the liver, it is necessary, against the background of strict monitoring of the patient's condition, to reduce the rate of intravenous infusion of the solution in order to prevent the occurrence of nausea or vomiting.
Drug interactions
The interaction of ornithine with other drugs / agents has not been established.
Ornilatex concentrate should be diluted only in the above solutions. The prepared solution for infusion should not be mixed with other medicines.
Analogs
Ornilatex analogs are Aminoplasmal Hepa, Aminoplasmal E 15, Hepa-Merz, Glutargin, Infezol 100, Larnamine, Ornithin-MBF, Orniprim, Ornithin Canon.
Terms and conditions of storage
Store in a place protected from light, out of reach of children, at a temperature not exceeding 25 ° C.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Ornilatex
According to the few reviews about Ornilatex, it is effective in the treatment of acute and chronic liver diseases accompanied by hyperammonemia. Patients note that the drug reduces the increased level of ammonia in the body, helps to normalize protein metabolism, relieves pain in the right hypochondrium and improves general condition.
There are no complaints about the development of side effects.
Ornilatex price in pharmacies
The price of Ornilatex, a concentrate for the preparation of a solution for infusion (500 mg / ml), can be 1450-1600 rubles. for 10 ampoules of 10 ml.
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
